Q1 EPS Forecast for CARGO Therapeutics Boosted by Analyst

CARGO Therapeutics, Inc. (NASDAQ:CRGX) – Research analysts at William Blair boosted their Q1 2025 earnings estimates for shares of CARGO Therapeutics in a research report issued on Thursday, January 30th. William Blair analyst S. Corwin now anticipates that the company will earn ($0.66) per share for the quarter, up from their previous forecast of ($0.95). William Blair has a “Market Perform” rating on the stock. The consensus estimate for CARGO Therapeutics’ current full-year earnings is ($3.74) per share. William Blair also issued estimates for CARGO Therapeutics’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.77) EPS.

CARGO Therapeutics (NASDAQ:CRGX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.26.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. lowered shares of CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a research report on Thursday, January 30th. Piper Sandler lowered shares of CARGO Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $34.00 to $4.00 in a research report on Thursday, January 30th. HC Wainwright lowered shares of CARGO Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, January 30th. Truist Financial lowered shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the stock from $32.00 to $7.00 in a research report on Thursday, January 30th. Finally, Chardan Capital lowered shares of CARGO Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. According to MarketBeat, CARGO Therapeutics presently has an average rating of “Hold” and an average target price of $15.00.

CARGO Therapeutics Stock Up 1.4 %

Shares of NASDAQ:CRGX opened at $3.70 on Monday. The company’s 50 day moving average price is $14.02 and its two-hundred day moving average price is $17.12. CARGO Therapeutics has a 12-month low of $3.00 and a 12-month high of $33.92. The firm has a market cap of $170.31 million, a PE ratio of -0.87 and a beta of 2.12.

Institutional Trading of CARGO Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CRGX. The Manufacturers Life Insurance Company grew its stake in shares of CARGO Therapeutics by 20.3% during the second quarter. The Manufacturers Life Insurance Company now owns 159,019 shares of the company’s stock worth $2,611,000 after buying an additional 26,808 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of CARGO Therapeutics during the third quarter worth $234,000. Charles Schwab Investment Management Inc. grew its stake in shares of CARGO Therapeutics by 87.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 295,960 shares of the company’s stock worth $5,460,000 after buying an additional 138,261 shares during the last quarter. FMR LLC grew its stake in shares of CARGO Therapeutics by 1.1% during the third quarter. FMR LLC now owns 6,954,476 shares of the company’s stock worth $128,310,000 after buying an additional 77,508 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of CARGO Therapeutics by 437.8% during the third quarter. BNP Paribas Financial Markets now owns 11,438 shares of the company’s stock worth $211,000 after buying an additional 9,311 shares during the last quarter. Institutional investors own 93.16% of the company’s stock.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.